Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (762)	7/26/2001 2:02:35 PM
From: tuck	Respond to of 1784

A few miscellany . . . >>NEW YORK, July 26 (Reuters) - UBS Warburg on Thursday said it started coverage of Pharmacopeia Inc. (NasdaqNM:PCOP - news), which helps develop and test new drugs and chemicals, with a buy rating and set the price target at $23 in anticipation that the company may separate its loss-making drug discovery unit. Pharmacopeia on July 12 said it would post a second-quarter loss of between 8 cents and 10 cents, blaming much of that on lower-than-expected drug discovery unit results. ``We expect management to separate its cash burning Drug Discovery business - through a subsidiary IPO or direct sale,'' analyst Michael Clulow said. The company's shares rose 1.38 percent to $16.85 on the Nasdaq. Shares are off 52-week highs of $49.<< snip This would make PCOP a pure bioinformatics play. Meanwhile, AFFX gets a strong buy from CSFB; no details given. And EBIO, a consumables company with strong ties to ABI (which is up on earnings held up largely by strength in its consumables, IMO) gets whacked just because it announces that its going to announce earnings on 8/7? Trickle doesn't have much cash, but I have some, and I'm sore tempted to buy some down here. Cheers, Tuck